IP Library › Granted Patent US 10,011,486
Granted Patent B2
US 10,011,486 · App. 15/345,155 · Granted Jul 3, 2018

Tricalcium phosphates, their composites, implants incorporating them, and methods for their production

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,011,486
App. No.
15/345,155
Granted
Jul 3, 2018
Kind
B2
Abstract

Methods for the synthesis of tricalcium phosphates are presented, as well as a series of specific reaction parameters that can be adjusted to tailor, in specific ways, properties in the tricalcium phosphate precursor precipitate. Particulate tricalcium phosphate compositions having an average crystal size of about 250 nm or less are provided. Compositions of the invention can be used as prosthetic implants and coatings for prosthetic implants.

Claims (20)

1. A composition comprising particulate tricalcium phosphate (TCP) having an average particle size of about 5 μm or less and an average crystal size of about 250 nm or less, wherein the particulate TCP comprises α-TCP.

2. The composition of claim 1 , wherein the particulate TCP comprises pure α-TCP.

3. The composition of claim 1 , wherein the particulate TCP has an average crystal size of about 200 nm or less.

4. The composition of claim 1 , wherein the particulate TCP has an average crystal size of about 100 nm or less.

5. The composition of claim 1 , wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article transmits about 50% or more light having a wavelength in the range of about 150 nm to about 1,000 nm.

6. The composition of claim 5 , wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article transmits about 70% or more light having a wavelength in the range of about 150 nm to about 1,000 nm.

7. The composition of claim 1 , wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article has a compressive strength of 150 MPa or greater.

8. The composition of claim 1 , wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article has a density that is 90% of the theoretical density or greater.

9. A composition comprising particulate tricalcium phosphate (TCP) having an average particle size of about 5 m or less and an average crystal size of about 250 nm or less, wherein the particulate TCP comprises α-TCP, and wherein the TCP particles have an aspect ratio of about 1:1 to about 50:1.

10. The composition of claim 9 , wherein the TCP particles have an aspect ratio of about 3:1 or more.

11. The composition of claim 9 , wherein the particulate TCP comprises pure α-TCP.

12. The composition of claim 9 , wherein the particulate TCP has an average crystal size of about 200 nm or less.

13. The composition of claim 9 , wherein the particulate TCP has an average crystal size of about 100 nm or less.

14. The composition of claim 9 , wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article transmits about 50% or more light having a wavelength in the range of about 150 nm to about 1,000 nm.

15. The composition of claim 14 , wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article transmits about 70% or more light having a wavelength in the range of about 150 nm to about 1,000 run.

16. The composition of claim 9 , wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article has a compressive strength of 150 MPa or greater.

17. The composition of claim 9 , wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article has a density that is 90% of the theoretical density or greater.

18. A composition comprising particulate tricalcium phosphate (TCP) having an average particle size of about 5 μm or less, wherein the particulate TCP comprises α-TCP, and wherein when the particulate TCP is densified to form an article having a minimum dimension of about 0.5 cm or greater the article transmits about 50% or more light having a wavelength in the range of about 150 nm to about 1,000 nm.

19. The composition of claim 18 , wherein the particulate TCP comprises pure α-TCP.

20. The composition of claim 18 , wherein the TCP particles have an aspect ratio of about 3:1 or more.

Assignments (13)
SECURITY INTEREST Recorded Aug 11, 2024
From: XTANT MEDICAL, INC.; BACTERIN INTERNATIONAL, INC.; X-SPINE SYSTEMS, INC.; SURGALIGN SPV, INC.; XTANT MEDICAL HOLDINGS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 068539/0665 →
SECURITY INTEREST Recorded Aug 11, 2024
From: XTANT MEDICAL, INC.; BACTERIN INTERNATIONAL, INC.; X-SPINE SYSTEMS, INC.; SURGALIGN SPV, INC.; XTANT MEDICAL HOLDINGS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 068539/0492 →
SECURITY AGREEMENT SUPPLEMENT (TERM) Recorded Dec 22, 2023
From: XTANT MEDICAL HOLDINGS, INC.; XTANT MEDICAL, INC.; BACTERIN INTERNATIONAL, INC.; X-SPINE SYSTEMS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 066095/0635 →
SECURITY AGREEMENT SUPPLEMENT (REVOLVING) Recorded Dec 22, 2023
From: XTANT MEDICAL HOLDINGS, INC.; XTANT MEDICAL, INC.; BACTERIN INTERNATIONAL, INC.; X-SPINE SYSTEMS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 066095/0652 →
MERGER Recorded Oct 19, 2023
From: PIONEER SURGICAL TECHNOLOGY, INC.
To: PIONEER SURGICAL TECHNOLOGY NEWCO, INC.
Reel/Frame 065287/0641 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2023
From: PIONEER SURGICAL TECHNOLOGY NEWCO, INC.
To: XTANT MEDICAL HOLDINGS, INC.
Reel/Frame 065218/0590 →
RELEASE OF SECURITY INTEREST Recorded Jul 21, 2020
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.
Reel/Frame 053260/0398 →
RELEASE OF SECURITY INTEREST Recorded Jul 20, 2020
From: ARES CAPITAL CORPORATION, AS AGENT
To: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.; PARADIGM SPINE, LLC; FOURTH DIMENSION SPINE, LLC
Reel/Frame 053257/0652 →
SECURITY INTEREST Recorded Mar 8, 2019
From: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.; PARADIGM SPINE, LLC; FOURTH DIMENSION SPINE, LLC
To: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 048543/0505 →
SECURITY INTEREST Recorded Jun 6, 2018
From: RTI SURGICAL, INC.; PIONEER SURGICAL TECHNOLOGY, INC.; TUTOGEN MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A., AS THE ADMINISTRATIVE AGENT
Reel/Frame 046303/0926 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2017
From: AHN, EDWARD S.
To: ANGSTROM MEDICA, INC.
Reel/Frame 042213/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2017
From: ANGSTROM MEDICA, INC.
To: ANGSTROM ACQUISITION CORP. II
Reel/Frame 042213/0862 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2017
From: ANGSTROM ACQUISITION CORP. II
To: PIONEER SURGICAL TECHNOLOGY, INC.
Reel/Frame 042213/0900 →